Pfizer Inc stock page - price, fundamentals, dividends - iOCharts

Ticker
PFE

Price
49.92
Stock movement down
-0.47 (-0.93%)
Company name
Pfizer Inc
Exchange
(NYSE
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-General
Market cap
281.94B
Ent value
-
Price/Sales
3.05
Price/Book
-
Div yield
3.21%
Div growth
6.53%
Growth years
11
FCF payout
25.33%
Trailing P/E
11.29
Forward P/E
9.42
PEG
2.10
EPS growth
14.70%
1 year return
24.74%
3 year return
8.59%
5 year return
9.81%
10 year return
8.91%
Last updated: 2022-05-13

BUSINESS INSIGHT

Segment Revenues ($M)

Loading...
Covid-19 vaccine comments

BNT162b2, which was granted an emergency use authorization (EUA) in the U.S. in December 2020, and which contributed $154 million in sales in the fourth quarter

Geographic Revenues ($M)

Loading...

DIVIDENDS

Dividend yield - 5y

Loading...
Dividend yield data
Dividend per share1.60
Dividend yield3.21%
Payout frequencyQuarterly
Maximum yield5.34%
Average yield3.74%
Minimum yield2.61%
Discount to avg yield-16.70%
Upside potential-14.31%
Yield as % of max yield60.07%

Yield distribution (inverse percentile) - 5y

Loading...
Yield distribution data
Dividend yield3.21%
Current yield distribution88.73%
Yield at 100% (Min)2.61%
Yield at 90%3.17%
Yield at 80%3.34%
Yield at 50% (Median)3.77%
Yield at 20%4.07%
Yield at 10%4.26%
Yield at 0% (Max)5.34%

Dividend per share

Loading...
Dividend per share data
Years of growth11 years
CCC statusDividend Contender
Dividend per share1.60
Payout frequencyQuarterly
Ex-div date12 May 2022
EPS (TTM)-
EPS (1y forward)5.30
EPS growth (5y)14.70%
EPS growth (5y forward)5.37%

Dividend growth

Loading...
Please create a free account or log in to access this chart
Dividend growth data
PFES&P500
DGR MR2.56%-16.52%
DGR TTM5.33%4.37%
DGR 3 years6.58%3.88%
DGR 5 years6.53%4.73%
DGR 10 years7.48%8.30%
DGR 15 years3.66%5.82%
Time since last change announced155 days
EPS growth (5y)14.70%
EPS growth (5y forward)5.37%

Payout ratio

Loading...
Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM26.26%25.33%
Average--
Forward30.19%-

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E11.29
Price to OCF10.05
Price to FCF10.89
Price to EBITDA12.22
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales3.05
Price to Book-
EV to Sales-

FINANCIALS

Per share

Loading...
Per share data
Current share count5.65B
EPS (TTM)-
FCF per share (TTM)-

Income statement

Loading...
Income statement data
Revenue (TTM)92.37B
Gross profit (TTM)55.77B
Operating income (TTM)25.48B
Net income (TTM)24.97B
EPS (TTM)-
EPS (1y forward)5.30

Margins

Loading...
Margins data
Gross margin (TTM)60.38%
Operating margin (TTM)27.59%
Profit margin (TTM)27.03%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash1.94B
Net receivables15.74B
Total current assets59.69B
Goodwill49.21B
Intangible assets25.15B
Property, plant and equipment0.00
Total assets181.48B
Accounts payable5.58B
Short/Current long term debt37.00B
Total current liabilities42.67B
Total liabilities104.01B
Shareholder's equity77.46B
Net tangible assets-104.00M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)28.04B
Capital expenditures (TTM)2.16B
Free cash flow (TTM)25.89B
Dividends paid (TTM)6.56B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-
Return on Assets-
Return on Invested Capital-
Cash Return on Invested Capital-

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open50.38
Daily high50.79
Daily low49.68
Daily Volume22.1M
All-time high61.25
1y analyst estimate59.33
Beta0.72
EPS (TTM)-
Dividend per share1.60
Ex-div date12 May 2022
Next earnings date26 Jul 2022

Downside potential

Loading...
Downside potential data
PFES&P500
Current price drop from All-time high-18.50%-15.91%
Highest price drop-76.70%-56.47%
Date of highest drop2 Mar 20099 Mar 2009
Avg drop from high-30.11%-11.33%
Avg time to new high34 days12 days
Max time to new high5620 days1805 days
COMPANY DETAILS
PFE (Pfizer Inc) company logo
Marketcap
281.94B
Marketcap category
Large-cap
Description
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Employees
79000
SEC filings
CEO
Albert Bourla
Country
USA
City
New York
Stock type
Common stock
CCC status
Dividend Contender
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Pfizer Inc and its German partner BioNTech SE said on Friday they had agreed to push back deliveries of their COVID-19 vaccines to the European Union by three months as the bloc prepares for a potenti...
May 13, 2022
President Joe Biden said that the U.S. will share technologies used to make COVID-19 vaccines through the World Health Organization and is working on expanding rapid testing and antiviral treatments f...
May 13, 2022
U.S. biotechs and other health care stocks accounted for about 11% of all losses in U.S. equity values during the five-month period analyzed by The Business Journals.
May 13, 2022
The pill has become an increasingly important tool in the nation’s defense against COVID-19 as mask mandates have lifted and people have returned to their non-distanced lives.
May 13, 2022
Pfizer (PFE) is set to buy migraine drugmaker, Biohaven Pharmaceuticals for $11.6 billion. Bayer (BAYRY) beats Q1 earnings and sales expectations.
May 13, 2022
(Bloomberg) -- Pfizer Inc.’s $11.6 billion acquisition of Biohaven Pharmaceutical Holding Co. included a rarely used structure that could become a larger part of Big Pharma’s playbook in light of a to...
May 12, 2022
Several generic drugmakers will produce cheaper versions of Pfizer Inc's (NYSE: PFE) COVID-19 antiviral treatment Paxlovid at $25/course or less for low- and middle-income countries, Reuters reported ...
May 12, 2022
Stories circulating online in recent days that Pfizer said its COVID-19 vaccine is unsafe for pregnant women are not true, per reports.
May 12, 2022
Jean Hynes, manager of the Vanguard Health Care fund, is focused on big themes in healthcare—and stocks like Anthem and Eli Lilly.
May 12, 2022
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") will share new research during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7...
May 12, 2022
Next page